Business Context and Reporting Period
This Form 8-K was filed by Pro-Pharmaceuticals, Inc. (noted as Galectin Therapeutics Inc. in metadata) on January 25, 2008. The report details a private placement of securities and the entry into material definitive agreements with two accredited investors.
Key Financial Metrics and Transaction Details
- Transaction Date: January 25, 2008.
- Securities Issued: 50,000 Units.
- Proceeds Raised: $50,000.
- Unit Price: $1.00 per Unit.
- Unit Composition:
- One share of Series A 12% Convertible Preferred Stock.
- One Common Stock Purchase Warrant (exercise price: $1.50).
- One Common Stock Purchase Warrant (exercise price: $2.00).
- Historical Context: As of December 31, 2007, the company had previously issued 1,667,500 Units for $1,667,500 under similar terms.
Material Changes and Terms
The filing discloses the specific terms of the Series A 12% Convertible Preferred Stock and associated warrants:
- Dividends: Preferred Stock accrues interest at 12% per annum, payable at the company's option in cash or Common Stock valued at the higher of $1.00 or 100% of the 20-day weighted average price.
- Voting Rights: Each share of Preferred Stock carries one vote.
- Conversion: Convertible at the holder's option into one share of Common Stock. Mandatory conversion is triggered if the Common Stock closing price exceeds $3.00 for 15 consecutive trading days and a registration statement is effective.
- Warrant Terms: Warrants are exercisable for cash beginning 181 days after issuance and expire on the fourth anniversary. Exercise prices are adjustable for stock splits or reorganizations.
- Registration Rights: The company agreed to file a registration statement within 6 months of closing to register the resale of shares issuable upon conversion and warrant exercise.
Guidance, Risks, and Unusual Items
The filing does not provide forward-looking guidance, revenue projections, or management commentary regarding operational outlook. The transaction was conducted under Section 4(2) of the Securities Act of 1933 as an exemption from registration requirements, sold exclusively to accredited investors. No financial statements or pro forma information were included in this report.
Investor Verification Checklist
- Verify the total outstanding number of Series A Preferred Shares and Warrants following this issuance.
- Confirm the company's ability to meet the 6-month deadline for filing the registration statement for resale of securities.
- Review the company's cash position to determine if the $50,000 proceeds are sufficient for near-term operational needs.
- Monitor the Common Stock price relative to the $3.00 threshold for mandatory conversion of Preferred Stock.
- Check for any subsequent filings regarding the payment of the 12% accrued interest (cash vs. stock election).